EA027800B1 - Производные 3-фенилизохинолин-1(2h)-она в качестве ингибиторов parp-1 - Google Patents

Info

Publication number

EA027800B1

EA027800B1 EA201491026A EA201491026A EA027800B1 EA 027800 B1 EA027800 B1 EA 027800B1 EA 201491026 A EA201491026 A EA 201491026A EA 201491026 A EA201491026 A EA 201491026A EA 027800 B1 EA027800 B1 EA 027800B1

Authority

EA

Eurasian Patent Office

Prior art keywords

fluoro

formula

compound

isoquinolin

aminoethoxy

Prior art date

2011-11-25

Links

• Espacenet
• Global Dossier
• Discuss

• VZYRBVZOGGKAKY-UHFFFAOYSA-N 3-phenyl-2h-isoquinolin-1-one Chemical class C=1C2=CC=CC=C2C(O)=NC=1C1=CC=CC=C1 VZYRBVZOGGKAKY-UHFFFAOYSA-N 0.000 title abstract description 7
• 239000003112 inhibitor Substances 0.000 title description 12
• 101100407073 Caenorhabditis elegans parp-1 gene Proteins 0.000 title 1
• 150000001875 compounds Chemical class 0.000 claims abstract description 204
• 238000000034 method Methods 0.000 claims abstract description 72
• 201000011510 cancer Diseases 0.000 claims abstract description 20
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
• 230000000694 effects Effects 0.000 claims abstract description 13
• 201000010099 disease Diseases 0.000 claims abstract description 12
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
• 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 10
• 206010061218 Inflammation Diseases 0.000 claims abstract description 9
• 210000003169 central nervous system Anatomy 0.000 claims abstract description 9
• 230000004054 inflammatory process Effects 0.000 claims abstract description 9
• 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims abstract description 8
• 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims abstract description 8
• 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims abstract description 8
• BFJMBXAFUUTYIR-UHFFFAOYSA-N 4-(2-aminoethoxy)-3-(3,4-dichlorophenyl)-7-fluoro-2h-isoquinolin-1-one Chemical compound N1C(=O)C2=CC(F)=CC=C2C(OCCN)=C1C1=CC=C(Cl)C(Cl)=C1 BFJMBXAFUUTYIR-UHFFFAOYSA-N 0.000 claims abstract description 6
• IZPURWNXWPTMHH-UHFFFAOYSA-N 4-(2-aminoethoxy)-3-(4-bromophenyl)-7-fluoro-2h-isoquinolin-1-one Chemical compound N1C(=O)C2=CC(F)=CC=C2C(OCCN)=C1C1=CC=C(Br)C=C1 IZPURWNXWPTMHH-UHFFFAOYSA-N 0.000 claims abstract description 6
• OOMGICXJISMCLR-UHFFFAOYSA-N 4-(2-aminoethoxy)-3-(4-bromophenyl)-7,8-difluoro-2h-isoquinolin-1-one Chemical compound N1C(=O)C2=C(F)C(F)=CC=C2C(OCCN)=C1C1=CC=C(Br)C=C1 OOMGICXJISMCLR-UHFFFAOYSA-N 0.000 claims abstract description 5
• KYPCNLJQBLPDKY-UHFFFAOYSA-N 4-(2-aminoethoxy)-3-(4-chloro-3-methylphenyl)-7-fluoro-2h-isoquinolin-1-one Chemical compound C1=C(Cl)C(C)=CC(C2=C(C3=CC=C(F)C=C3C(=O)N2)OCCN)=C1 KYPCNLJQBLPDKY-UHFFFAOYSA-N 0.000 claims abstract description 5
• GSHBUCNCWYHWKA-UHFFFAOYSA-N 4-(2-aminoethoxy)-3-(4-chlorophenyl)-7-fluoro-2h-isoquinolin-1-one Chemical compound N1C(=O)C2=CC(F)=CC=C2C(OCCN)=C1C1=CC=C(Cl)C=C1 GSHBUCNCWYHWKA-UHFFFAOYSA-N 0.000 claims abstract description 5
• FPMIUVGZAHMUQO-UHFFFAOYSA-N 4-(2-aminoethoxy)-7-fluoro-3-(3-fluoro-4-methoxyphenyl)-2h-isoquinolin-1-one Chemical compound C1=C(F)C(OC)=CC=C1C1=C(OCCN)C2=CC=C(F)C=C2C(=O)N1 FPMIUVGZAHMUQO-UHFFFAOYSA-N 0.000 claims abstract description 5
• VYUKSMNSIRGBBM-UHFFFAOYSA-N 3-[4-(2-aminoethoxy)-7-fluoro-1-oxo-2h-isoquinolin-3-yl]benzonitrile Chemical compound N1C(=O)C2=CC(F)=CC=C2C(OCCN)=C1C1=CC=CC(C#N)=C1 VYUKSMNSIRGBBM-UHFFFAOYSA-N 0.000 claims abstract description 4
• POAFYPSDLXGQBX-UHFFFAOYSA-N 4-(2-aminoethoxy)-3-(3-bromo-4-morpholin-4-ylphenyl)-7-fluoro-2h-isoquinolin-1-one Chemical compound N1C(=O)C2=CC(F)=CC=C2C(OCCN)=C1C(C=C1Br)=CC=C1N1CCOCC1 POAFYPSDLXGQBX-UHFFFAOYSA-N 0.000 claims abstract description 4
• NALBIBKGPRRCCO-UHFFFAOYSA-N 4-(2-aminoethoxy)-7-fluoro-3-(4-fluorophenyl)-2h-isoquinolin-1-one Chemical compound N1C(=O)C2=CC(F)=CC=C2C(OCCN)=C1C1=CC=C(F)C=C1 NALBIBKGPRRCCO-UHFFFAOYSA-N 0.000 claims abstract description 4
• XIAODRJBQHVZIE-UHFFFAOYSA-N 4-(2-aminoethoxy)-7-fluoro-3-[3-(trifluoromethyl)phenyl]-2h-isoquinolin-1-one Chemical compound N1C(=O)C2=CC(F)=CC=C2C(OCCN)=C1C1=CC=CC(C(F)(F)F)=C1 XIAODRJBQHVZIE-UHFFFAOYSA-N 0.000 claims abstract description 4
• -1 dioxolyl Chemical group 0.000 claims description 79
• 229910052739 hydrogen Inorganic materials 0.000 claims description 44
• 229910052700 potassium Inorganic materials 0.000 claims description 40
• 108090000623 proteins and genes Proteins 0.000 claims description 32
• 102000004169 proteins and genes Human genes 0.000 claims description 27
• 150000003839 salts Chemical class 0.000 claims description 27
• 238000011282 treatment Methods 0.000 claims description 25
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 19
• 239000001257 hydrogen Substances 0.000 claims description 17
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical group O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 11
• 229910052736 halogen Inorganic materials 0.000 claims description 11
• 150000002367 halogens Chemical class 0.000 claims description 11
• 125000000623 heterocyclic group Chemical group 0.000 claims description 11
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 11
• 229960004964 temozolomide Drugs 0.000 claims description 11
• 229940100198 alkylating agent Drugs 0.000 claims description 9
• 239000002168 alkylating agent Substances 0.000 claims description 9
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 9
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 8
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
• 229910052757 nitrogen Inorganic materials 0.000 claims description 8
• 229910052794 bromium Inorganic materials 0.000 claims description 7
• 239000003795 chemical substances by application Substances 0.000 claims description 7
• 229940127089 cytotoxic agent Drugs 0.000 claims description 7
• 239000003814 drug Substances 0.000 claims description 7
• 229910052731 fluorine Inorganic materials 0.000 claims description 7
• 230000001404 mediated effect Effects 0.000 claims description 7
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 6
• 239000002246 antineoplastic agent Substances 0.000 claims description 6
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
• 230000006378 damage Effects 0.000 claims description 6
• 239000011737 fluorine Substances 0.000 claims description 6
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
• 125000006239 protecting group Chemical group 0.000 claims description 6
• 125000000597 dioxinyl group Chemical group 0.000 claims description 5
• 125000005842 heteroatom Chemical group 0.000 claims description 5
• 150000002431 hydrogen Chemical class 0.000 claims description 5
• 230000002401 inhibitory effect Effects 0.000 claims description 5
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
• 229910052801 chlorine Inorganic materials 0.000 claims description 4
• 239000000460 chlorine Substances 0.000 claims description 4
• 239000003085 diluting agent Substances 0.000 claims description 4
• 239000003937 drug carrier Substances 0.000 claims description 4
• 230000003902 lesion Effects 0.000 claims description 4
• 238000004519 manufacturing process Methods 0.000 claims description 4
• 229910052760 oxygen Chemical group 0.000 claims description 4
• 239000001301 oxygen Chemical group 0.000 claims description 4
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
• 230000002152 alkylating effect Effects 0.000 claims description 3
• 238000011319 anticancer therapy Methods 0.000 claims description 3
• 210000000653 nervous system Anatomy 0.000 claims description 3
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
• 230000008707 rearrangement Effects 0.000 claims description 3
• 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
• 102100027939 Serine/threonine-protein kinase PAK 2 Human genes 0.000 claims description 2
• 101710148167 Serine/threonine-protein kinase PAK 2 Proteins 0.000 claims description 2
• 230000003287 optical effect Effects 0.000 claims description 2
• 238000002360 preparation method Methods 0.000 claims description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 2
• 206010028980 Neoplasm Diseases 0.000 abstract description 20
• 208000001738 Nervous System Trauma Diseases 0.000 abstract 1
• 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 abstract 1
• 102100023652 Poly [ADP-ribose] polymerase 2 Human genes 0.000 abstract 1
• 101710144590 Poly [ADP-ribose] polymerase 2 Proteins 0.000 abstract 1
• 208000028412 nervous system injury Diseases 0.000 abstract 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 74
• 238000005481 NMR spectroscopy Methods 0.000 description 66
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
• 239000002904 solvent Substances 0.000 description 26
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
• 239000000203 mixture Substances 0.000 description 21
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
• NBJDSMIOWPVWRW-UHFFFAOYSA-N 2h-oxazepin-5-one Chemical compound O=C1C=CNOC=C1 NBJDSMIOWPVWRW-UHFFFAOYSA-N 0.000 description 17
• 239000007858 starting material Substances 0.000 description 17
• 238000012360 testing method Methods 0.000 description 17
• ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
• 239000012071 phase Substances 0.000 description 14
• 239000000243 solution Substances 0.000 description 13
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 12
• 229910052796 boron Inorganic materials 0.000 description 12
• 125000001246 bromo group Chemical group Br* 0.000 description 12
• 238000006243 chemical reaction Methods 0.000 description 12
• 230000000875 corresponding effect Effects 0.000 description 12
• 239000000523 sample Substances 0.000 description 12
• 239000011734 sodium Substances 0.000 description 12
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 12
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 11
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
• 210000004027 cell Anatomy 0.000 description 11
• 239000011541 reaction mixture Substances 0.000 description 11
• 235000015424 sodium Nutrition 0.000 description 11
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 10
• 238000010992 reflux Methods 0.000 description 10
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
• 230000009466 transformation Effects 0.000 description 10
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
• 125000003118 aryl group Chemical group 0.000 description 9
• 230000002829 reductive effect Effects 0.000 description 9
• 239000007787 solid Substances 0.000 description 9
• 239000000126 substance Substances 0.000 description 9
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 8
• 238000004458 analytical method Methods 0.000 description 8
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 8
• 229910000024 caesium carbonate Inorganic materials 0.000 description 8
• 239000012043 crude product Substances 0.000 description 8
• HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 8
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 8
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
• 239000011591 potassium Substances 0.000 description 8
• 229960003975 potassium Drugs 0.000 description 8
• 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 7
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
• 239000002585 base Substances 0.000 description 7
• 229940125904 compound 1 Drugs 0.000 description 7
• 238000003818 flash chromatography Methods 0.000 description 7
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 6
• 239000003054 catalyst Substances 0.000 description 6
• MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 6
• 230000005764 inhibitory process Effects 0.000 description 6
• 230000003993 interaction Effects 0.000 description 6
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
• 230000035772 mutation Effects 0.000 description 6
• 230000008439 repair process Effects 0.000 description 6
• 229910000029 sodium carbonate Inorganic materials 0.000 description 6
• 108020004414 DNA Proteins 0.000 description 5
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
• 241000699670 Mus sp. Species 0.000 description 5
• 230000015572 biosynthetic process Effects 0.000 description 5
• 238000009835 boiling Methods 0.000 description 5
• 239000003153 chemical reaction reagent Substances 0.000 description 5
• 238000007796 conventional method Methods 0.000 description 5
• 230000007812 deficiency Effects 0.000 description 5
• 238000010511 deprotection reaction Methods 0.000 description 5
• 238000000132 electrospray ionisation Methods 0.000 description 5
• 230000014759 maintenance of location Effects 0.000 description 5
• 210000001672 ovary Anatomy 0.000 description 5
• 239000000725 suspension Substances 0.000 description 5
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
• 210000004881 tumor cell Anatomy 0.000 description 5
• WXLCDTBTIVJDCE-UHFFFAOYSA-N 1,4-oxazepine Chemical compound O1C=CC=NC=C1 WXLCDTBTIVJDCE-UHFFFAOYSA-N 0.000 description 4
• 206010006187 Breast cancer Diseases 0.000 description 4
• 230000005778 DNA damage Effects 0.000 description 4
• 231100000277 DNA damage Toxicity 0.000 description 4
• 230000033616 DNA repair Effects 0.000 description 4
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
• 241001465754 Metazoa Species 0.000 description 4
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
• 239000002253 acid Substances 0.000 description 4
• 125000003545 alkoxy group Chemical group 0.000 description 4
• 125000000217 alkyl group Chemical group 0.000 description 4
• 230000027455 binding Effects 0.000 description 4
• ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
• 210000000481 breast Anatomy 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• 239000000284 extract Substances 0.000 description 4
• 125000001072 heteroaryl group Chemical group 0.000 description 4
• 238000001990 intravenous administration Methods 0.000 description 4
• VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical class C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 description 4
• 229920000609 methyl cellulose Polymers 0.000 description 4
• 239000001923 methylcellulose Substances 0.000 description 4
• 235000010981 methylcellulose Nutrition 0.000 description 4
• 230000010287 polarization Effects 0.000 description 4
• 229910000027 potassium carbonate Inorganic materials 0.000 description 4
• 238000002953 preparative HPLC Methods 0.000 description 4
• VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 4
• 238000000926 separation method Methods 0.000 description 4
• 238000009097 single-agent therapy Methods 0.000 description 4
• MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
• YWWDBCBWQNCYNR-UHFFFAOYSA-N trimethylphosphine Chemical compound CP(C)C YWWDBCBWQNCYNR-UHFFFAOYSA-N 0.000 description 4
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
• BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 4
• 230000004614 tumor growth Effects 0.000 description 4
• 239000011701 zinc Substances 0.000 description 4
• 229910052725 zinc Inorganic materials 0.000 description 4
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
• RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 206010025323 Lymphomas Diseases 0.000 description 3
• 101000806171 Oryctolagus cuniculus Dehydrogenase/reductase SDR family member 4 Proteins 0.000 description 3
• 108091026813 Poly(ADPribose) Proteins 0.000 description 3
• 229930006000 Sucrose Natural products 0.000 description 3
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
• 125000003277 amino group Chemical group 0.000 description 3
• 229910052786 argon Inorganic materials 0.000 description 3
• 229910052799 carbon Inorganic materials 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 125000000753 cycloalkyl group Chemical group 0.000 description 3
• 230000007547 defect Effects 0.000 description 3
• 206010012601 diabetes mellitus Diseases 0.000 description 3
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
• 235000019253 formic acid Nutrition 0.000 description 3
• 239000012634 fragment Substances 0.000 description 3
• 125000000524 functional group Chemical group 0.000 description 3
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
• 231100000518 lethal Toxicity 0.000 description 3
• 230000001665 lethal effect Effects 0.000 description 3
• 229910052751 metal Inorganic materials 0.000 description 3
• 239000002184 metal Substances 0.000 description 3
• 150000007522 mineralic acids Chemical class 0.000 description 3
• 150000007524 organic acids Chemical class 0.000 description 3
• NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
• 229910052698 phosphorus Inorganic materials 0.000 description 3
• 230000036470 plasma concentration Effects 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 238000012216 screening Methods 0.000 description 3
• 239000000741 silica gel Substances 0.000 description 3
• 229910002027 silica gel Inorganic materials 0.000 description 3
• UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
• 238000003756 stirring Methods 0.000 description 3
• 239000005720 sucrose Substances 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
• 230000001225 therapeutic effect Effects 0.000 description 3
• 231100000419 toxicity Toxicity 0.000 description 3
• 230000001988 toxicity Effects 0.000 description 3
• 238000000844 transformation Methods 0.000 description 3
• CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
• SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
• SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
• 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 2
• AXQKNEPHUZHEDL-UHFFFAOYSA-N 3-(3-bromophenyl)-7-fluoro-1-phenylmethoxyisoquinolin-4-ol Chemical compound C12=CC(F)=CC=C2C(O)=C(C=2C=C(Br)C=CC=2)N=C1OCC1=CC=CC=C1 AXQKNEPHUZHEDL-UHFFFAOYSA-N 0.000 description 2
• NLGZHPNSNJUAJV-UHFFFAOYSA-N 3-(4-bromophenyl)-7-fluoro-1-phenylmethoxyisoquinolin-4-ol Chemical compound C12=CC(F)=CC=C2C(O)=C(C=2C=CC(Br)=CC=2)N=C1OCC1=CC=CC=C1 NLGZHPNSNJUAJV-UHFFFAOYSA-N 0.000 description 2
• SBEWIVZENYLIBU-UHFFFAOYSA-N 3-(4-chlorophenyl)-7-fluoro-4-hydroxy-2h-isoquinolin-1-one Chemical compound N1C(=O)C2=CC(F)=CC=C2C(O)=C1C1=CC=C(Cl)C=C1 SBEWIVZENYLIBU-UHFFFAOYSA-N 0.000 description 2
• 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 2
• YWLGMJJJPUBMDZ-UHFFFAOYSA-N 4-(2-aminoethoxy)-7-fluoro-3-(4-pyrrolidin-1-ylphenyl)-2h-isoquinolin-1-one;hydrochloride Chemical compound Cl.N1C(=O)C2=CC(F)=CC=C2C(OCCN)=C1C(C=C1)=CC=C1N1CCCC1 YWLGMJJJPUBMDZ-UHFFFAOYSA-N 0.000 description 2
• KFARIFHMSPSXTM-UHFFFAOYSA-N 4-(7-fluoro-4-hydroxy-1-oxo-2h-isoquinolin-3-yl)benzonitrile Chemical compound N1C(=O)C2=CC(F)=CC=C2C(O)=C1C1=CC=C(C#N)C=C1 KFARIFHMSPSXTM-UHFFFAOYSA-N 0.000 description 2
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
• USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
• 239000005695 Ammonium acetate Substances 0.000 description 2
• DFVIJYJCOQBXIA-UHFFFAOYSA-N BrCCNC(O)=O.C(C)(C)(C)OC(C)(C)C Chemical compound BrCCNC(O)=O.C(C)(C)(C)OC(C)(C)C DFVIJYJCOQBXIA-UHFFFAOYSA-N 0.000 description 2
• 241000282421 Canidae Species 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
• 201000009030 Carcinoma Diseases 0.000 description 2
• 229940126062 Compound A Drugs 0.000 description 2
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
• YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
• 108010033040 Histones Proteins 0.000 description 2
• 102000006947 Histones Human genes 0.000 description 2
• 206010021143 Hypoxia Diseases 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
• DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
• 229920001213 Polysorbate 20 Polymers 0.000 description 2
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
• 108010029485 Protein Isoforms Proteins 0.000 description 2
• 102000001708 Protein Isoforms Human genes 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
• DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
• 125000003342 alkenyl group Chemical group 0.000 description 2
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
• 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 2
• 125000003282 alkyl amino group Chemical group 0.000 description 2
• 125000000304 alkynyl group Chemical group 0.000 description 2
• VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
• 235000019257 ammonium acetate Nutrition 0.000 description 2
• 229940043376 ammonium acetate Drugs 0.000 description 2
• VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
• 239000004037 angiogenesis inhibitor Substances 0.000 description 2
• 230000000259 anti-tumor effect Effects 0.000 description 2
• 239000008346 aqueous phase Substances 0.000 description 2
• 206010003246 arthritis Diseases 0.000 description 2
• 125000001769 aryl amino group Chemical group 0.000 description 2
• 125000004104 aryloxy group Chemical group 0.000 description 2
• RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 2
• 229910001863 barium hydroxide Inorganic materials 0.000 description 2
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
• SUMDYPCJJOFFON-UHFFFAOYSA-N beta-hydroxyethanesulfonic acid Natural products OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 125000002837 carbocyclic group Chemical group 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
• 230000004706 cardiovascular dysfunction Effects 0.000 description 2
• 230000022131 cell cycle Effects 0.000 description 2
• 210000003679 cervix uteri Anatomy 0.000 description 2
• 230000000973 chemotherapeutic effect Effects 0.000 description 2
• 206010009887 colitis Diseases 0.000 description 2
• 210000001072 colon Anatomy 0.000 description 2
• 229940126543 compound 14 Drugs 0.000 description 2
• 229940125810 compound 20 Drugs 0.000 description 2
• 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 description 2
• LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
• 231100000433 cytotoxic Toxicity 0.000 description 2
• 230000001472 cytotoxic effect Effects 0.000 description 2
• 239000008121 dextrose Substances 0.000 description 2
• 125000004663 dialkyl amino group Chemical group 0.000 description 2
• FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
• CNXMDTWQWLGCPE-UHFFFAOYSA-N ditert-butyl-(2-phenylphenyl)phosphane Chemical group CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1 CNXMDTWQWLGCPE-UHFFFAOYSA-N 0.000 description 2
• 239000000975 dye Substances 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
• 230000006846 excision repair Effects 0.000 description 2
• 239000012091 fetal bovine serum Substances 0.000 description 2
• 125000001153 fluoro group Chemical group F* 0.000 description 2
• 210000004602 germ cell Anatomy 0.000 description 2
• JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
• 201000005787 hematologic cancer Diseases 0.000 description 2
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
• 125000006517 heterocyclyl carbonyl group Chemical group 0.000 description 2
• 230000006801 homologous recombination Effects 0.000 description 2
• 238000002744 homologous recombination Methods 0.000 description 2
• 238000005984 hydrogenation reaction Methods 0.000 description 2
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
• 230000007954 hypoxia Effects 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 239000000543 intermediate Substances 0.000 description 2
• 229910052740 iodine Inorganic materials 0.000 description 2
• PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
• 150000002500 ions Chemical class 0.000 description 2
• 150000003951 lactams Chemical class 0.000 description 2
• 235000010445 lecithin Nutrition 0.000 description 2
• 239000000787 lecithin Substances 0.000 description 2
• 229940067606 lecithin Drugs 0.000 description 2
• 208000032839 leukemia Diseases 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• 229940098779 methanesulfonic acid Drugs 0.000 description 2
• 230000011987 methylation Effects 0.000 description 2
• 238000007069 methylation reaction Methods 0.000 description 2
• NSBNSZAXNUGWDJ-UHFFFAOYSA-O monopyridin-1-ium tribromide Chemical compound Br[Br-]Br.C1=CC=[NH+]C=C1 NSBNSZAXNUGWDJ-UHFFFAOYSA-O 0.000 description 2
• OQJBFFCUFALWQL-UHFFFAOYSA-N n-(piperidine-1-carbonylimino)piperidine-1-carboxamide Chemical compound C1CCCCN1C(=O)N=NC(=O)N1CCCCC1 OQJBFFCUFALWQL-UHFFFAOYSA-N 0.000 description 2
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
• 108020004707 nucleic acids Proteins 0.000 description 2
• 102000039446 nucleic acids Human genes 0.000 description 2
• 150000007523 nucleic acids Chemical class 0.000 description 2
• 229910052763 palladium Inorganic materials 0.000 description 2
• 150000002940 palladium Chemical class 0.000 description 2
• NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
• YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
• RZFVLEJOHSLEFR-UHFFFAOYSA-N phenanthridone Chemical class C1=CC=C2C(O)=NC3=CC=CC=C3C2=C1 RZFVLEJOHSLEFR-UHFFFAOYSA-N 0.000 description 2
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
• NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 2
• 229910000105 potassium hydride Inorganic materials 0.000 description 2
• KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 230000000770 proinflammatory effect Effects 0.000 description 2
• 210000002307 prostate Anatomy 0.000 description 2
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
• 238000013207 serial dilution Methods 0.000 description 2
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
• 235000017557 sodium bicarbonate Nutrition 0.000 description 2
• 229910000104 sodium hydride Inorganic materials 0.000 description 2
• HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
• SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 2
• 239000000600 sorbitol Substances 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 239000008223 sterile water Substances 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• FTAQCAHRPLOJEG-UHFFFAOYSA-N tert-butyl N-[2-[3-(3,4-dichlorophenyl)-7-fluoro-1-phenylmethoxyisoquinolin-4-yl]oxyethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOc1c(nc(OCc2ccccc2)c2cc(F)ccc12)-c1ccc(Cl)c(Cl)c1 FTAQCAHRPLOJEG-UHFFFAOYSA-N 0.000 description 2
• WFNRLFIRQUIYIT-UHFFFAOYSA-N tert-butyl N-[2-[[3-(4-cyanophenyl)-7-fluoro-1-oxo-2H-isoquinolin-4-yl]oxy]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOc1c([nH]c(=O)c2cc(F)ccc12)-c1ccc(cc1)C#N WFNRLFIRQUIYIT-UHFFFAOYSA-N 0.000 description 2
• QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 238000004809 thin layer chromatography Methods 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 2
• JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
• UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 1
• GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
• HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
• IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
• 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
• HLHSUNWAPXINQU-GQCTYLIASA-N (E)-3-(3,4-dihydroxyphenyl)-N-prop-2-ynylprop-2-enamide Chemical compound OC=1C=C(C=CC=1O)/C=C/C(=O)NCC#C HLHSUNWAPXINQU-GQCTYLIASA-N 0.000 description 1
• 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
• ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 1
• WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
• OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
• UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
• 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
• 125000006039 1-hexenyl group Chemical group 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• 125000006017 1-propenyl group Chemical group 0.000 description 1
• 238000005160 1H NMR spectroscopy Methods 0.000 description 1
• JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
• 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
• 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
• 125000006024 2-pentenyl group Chemical group 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
• RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
• MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
• UYVGNVCTQKHOHP-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yl)-7-fluoro-4-hydroxy-2h-isoquinolin-1-one Chemical compound C1=C2OCOC2=CC(C2=C(C3=CC=C(F)C=C3C(=O)N2)O)=C1 UYVGNVCTQKHOHP-UHFFFAOYSA-N 0.000 description 1
• AAMDZIJNUAAZHM-UHFFFAOYSA-N 3-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-fluoro-4-hydroxy-2h-isoquinolin-1-one Chemical compound O1CCOC2=CC(C3=C(C4=CC=C(F)C=C4C(=O)N3)O)=CC=C21 AAMDZIJNUAAZHM-UHFFFAOYSA-N 0.000 description 1
• HMPKLFLQRLJCIV-UHFFFAOYSA-N 3-(3,4-dichlorophenyl)-7-fluoro-1-phenylmethoxyisoquinolin-4-ol Chemical compound C12=CC(F)=CC=C2C(O)=C(C=2C=C(Cl)C(Cl)=CC=2)N=C1OCC1=CC=CC=C1 HMPKLFLQRLJCIV-UHFFFAOYSA-N 0.000 description 1
• UUZZOYNGHJUKJL-UHFFFAOYSA-N 3-(3,4-dichlorophenyl)-7-fluoro-4-hydroxy-2h-isoquinolin-1-one Chemical compound N1C(=O)C2=CC(F)=CC=C2C(O)=C1C1=CC=C(Cl)C(Cl)=C1 UUZZOYNGHJUKJL-UHFFFAOYSA-N 0.000 description 1
• YEKSJGXOFNHPTC-UHFFFAOYSA-N 3-(3,4-difluorophenyl)-7-fluoro-4-hydroxy-2h-isoquinolin-1-one Chemical compound N1C(=O)C2=CC(F)=CC=C2C(O)=C1C1=CC=C(F)C(F)=C1 YEKSJGXOFNHPTC-UHFFFAOYSA-N 0.000 description 1
• RYEQAYXVNORFFK-UHFFFAOYSA-N 3-(3-bromo-4-morpholin-4-ylphenyl)-7-fluoro-4-hydroxy-2h-isoquinolin-1-one Chemical compound N1C(=O)C2=CC(F)=CC=C2C(O)=C1C(C=C1Br)=CC=C1N1CCOCC1 RYEQAYXVNORFFK-UHFFFAOYSA-N 0.000 description 1
• NGSGGPFMZHKIEP-UHFFFAOYSA-N 3-(4-bromophenyl)-7,8-difluoro-4-hydroxy-2h-isoquinolin-1-one Chemical compound N1C(=O)C2=C(F)C(F)=CC=C2C(O)=C1C1=CC=C(Br)C=C1 NGSGGPFMZHKIEP-UHFFFAOYSA-N 0.000 description 1
• JQRDGDGWERYNTG-UHFFFAOYSA-N 3-(4-chloro-3-methylphenyl)-7-fluoro-4-hydroxy-2h-isoquinolin-1-one Chemical compound C1=C(Cl)C(C)=CC(C2=C(C3=CC=C(F)C=C3C(=O)N2)O)=C1 JQRDGDGWERYNTG-UHFFFAOYSA-N 0.000 description 1
• VKYJASPPXLHNON-UHFFFAOYSA-N 3-(7-fluoro-4-hydroxy-1-phenylmethoxyisoquinolin-3-yl)benzonitrile Chemical compound C12=CC(F)=CC=C2C(O)=C(C=2C=C(C=CC=2)C#N)N=C1OCC1=CC=CC=C1 VKYJASPPXLHNON-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
• QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
• JARDVHFUDGCKPB-UHFFFAOYSA-N 4-(2-aminoethoxy)-3-(1,3-benzodioxol-5-yl)-7-fluoro-2h-isoquinolin-1-one;hydrochloride Chemical compound Cl.C1=C2OCOC2=CC(C2=C(C3=CC=C(F)C=C3C(=O)N2)OCCN)=C1 JARDVHFUDGCKPB-UHFFFAOYSA-N 0.000 description 1
• OKZVWHVKFPRNLX-UHFFFAOYSA-N 4-(2-aminoethoxy)-3-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-fluoro-2h-isoquinolin-1-one Chemical compound O1CCOC2=CC(C3=C(C4=CC=C(F)C=C4C(=O)N3)OCCN)=CC=C21 OKZVWHVKFPRNLX-UHFFFAOYSA-N 0.000 description 1
• JNZDIFXXOMRNBP-UHFFFAOYSA-N 4-(2-aminoethoxy)-3-(3,4-dichlorophenyl)-7-fluoro-2h-isoquinolin-1-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N1C(=O)C2=CC(F)=CC=C2C(OCCN)=C1C1=CC=C(Cl)C(Cl)=C1 JNZDIFXXOMRNBP-UHFFFAOYSA-N 0.000 description 1
• QFSVPWVQQYIOPU-UHFFFAOYSA-N 4-(2-aminoethoxy)-3-(3,4-difluorophenyl)-7-fluoro-2h-isoquinolin-1-one;hydrochloride Chemical compound Cl.N1C(=O)C2=CC(F)=CC=C2C(OCCN)=C1C1=CC=C(F)C(F)=C1 QFSVPWVQQYIOPU-UHFFFAOYSA-N 0.000 description 1
• WMVFZKMYPVWPDL-UHFFFAOYSA-N 4-(2-aminoethoxy)-3-(3-bromo-4-morpholin-4-ylphenyl)-7-fluoro-2h-isoquinolin-1-one;hydrochloride Chemical compound Cl.N1C(=O)C2=CC(F)=CC=C2C(OCCN)=C1C(C=C1Br)=CC=C1N1CCOCC1 WMVFZKMYPVWPDL-UHFFFAOYSA-N 0.000 description 1
• AUSDJKWCUGOMRT-UHFFFAOYSA-N 4-(2-aminoethoxy)-3-(3-bromo-4-pyrrolidin-1-ylphenyl)-7-fluoro-2h-isoquinolin-1-one Chemical compound N1C(=O)C2=CC(F)=CC=C2C(OCCN)=C1C(C=C1Br)=CC=C1N1CCCC1 AUSDJKWCUGOMRT-UHFFFAOYSA-N 0.000 description 1
• WUPJHFFVLMGEDF-UHFFFAOYSA-N 4-(2-aminoethoxy)-3-(4-bromophenyl)-7,8-difluoro-2H-isoquinolin-1-one hydrochloride Chemical compound Cl.NCCOc1c([nH]c(=O)c2c(F)c(F)ccc12)-c1ccc(Br)cc1 WUPJHFFVLMGEDF-UHFFFAOYSA-N 0.000 description 1
• SYYRQINZNLEVKO-UHFFFAOYSA-N 4-(2-aminoethoxy)-3-(4-chloro-3-methylphenyl)-7-fluoro-2h-isoquinolin-1-one;hydrochloride Chemical compound Cl.C1=C(Cl)C(C)=CC(C2=C(C3=CC=C(F)C=C3C(=O)N2)OCCN)=C1 SYYRQINZNLEVKO-UHFFFAOYSA-N 0.000 description 1
• KXEUCRKBELFYHS-UHFFFAOYSA-N 4-(2-aminoethoxy)-3-(4-chlorophenyl)-7-fluoro-2h-isoquinolin-1-one;hydrochloride Chemical compound Cl.N1C(=O)C2=CC(F)=CC=C2C(OCCN)=C1C1=CC=C(Cl)C=C1 KXEUCRKBELFYHS-UHFFFAOYSA-N 0.000 description 1
• OYZNSNODTABQGU-UHFFFAOYSA-N 4-(2-aminoethoxy)-7-fluoro-3-(3-fluoro-4-methoxyphenyl)-2h-isoquinolin-1-one;hydrochloride Chemical compound Cl.C1=C(F)C(OC)=CC=C1C1=C(OCCN)C2=CC=C(F)C=C2C(=O)N1 OYZNSNODTABQGU-UHFFFAOYSA-N 0.000 description 1
• JAFVQQVFZYJOGN-UHFFFAOYSA-N 4-(2-aminoethoxy)-7-fluoro-3-(4-fluorophenyl)-2h-isoquinolin-1-one;hydrochloride Chemical compound Cl.N1C(=O)C2=CC(F)=CC=C2C(OCCN)=C1C1=CC=C(F)C=C1 JAFVQQVFZYJOGN-UHFFFAOYSA-N 0.000 description 1
• ASAJWQQKKLRVTD-UHFFFAOYSA-N 4-(2-aminoethoxy)-7-fluoro-3-(4-methylsulfonylphenyl)-2h-isoquinolin-1-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(OCCN)C2=CC=C(F)C=C2C(=O)N1 ASAJWQQKKLRVTD-UHFFFAOYSA-N 0.000 description 1
• KNTCUYSHPYVNKB-UHFFFAOYSA-N 4-(2-aminoethoxy)-7-fluoro-3-(4-methylsulfonylphenyl)-2h-isoquinolin-1-one;hydrochloride Chemical compound Cl.C1=CC(S(=O)(=O)C)=CC=C1C1=C(OCCN)C2=CC=C(F)C=C2C(=O)N1 KNTCUYSHPYVNKB-UHFFFAOYSA-N 0.000 description 1
• JRBYIBUDHHFPFU-UHFFFAOYSA-N 4-(2-aminoethoxy)-7-fluoro-3-(4-morpholin-4-ylphenyl)-2h-isoquinolin-1-one;hydrochloride Chemical compound Cl.N1C(=O)C2=CC(F)=CC=C2C(OCCN)=C1C(C=C1)=CC=C1N1CCOCC1 JRBYIBUDHHFPFU-UHFFFAOYSA-N 0.000 description 1
• VMEBHSKHEHHQER-UHFFFAOYSA-N 4-(2-aminoethoxy)-7-fluoro-3-[3-(trifluoromethyl)phenyl]-2h-isoquinolin-1-one;hydrochloride Chemical compound Cl.N1C(=O)C2=CC(F)=CC=C2C(OCCN)=C1C1=CC=CC(C(F)(F)F)=C1 VMEBHSKHEHHQER-UHFFFAOYSA-N 0.000 description 1
• NPEPDEVROKGNBZ-UHFFFAOYSA-N 4-[4-(2-aminoethoxy)-7-fluoro-1-oxo-2h-isoquinolin-3-yl]benzonitrile;hydrochloride Chemical compound Cl.N1C(=O)C2=CC(F)=CC=C2C(OCCN)=C1C1=CC=C(C#N)C=C1 NPEPDEVROKGNBZ-UHFFFAOYSA-N 0.000 description 1
• PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
• SMFOMPSEEGKGOF-UHFFFAOYSA-N 7-fluoro-3-(3-fluoro-4-methoxyphenyl)-4-hydroxy-2h-isoquinolin-1-one Chemical compound C1=C(F)C(OC)=CC=C1C1=C(O)C2=CC=C(F)C=C2C(=O)N1 SMFOMPSEEGKGOF-UHFFFAOYSA-N 0.000 description 1
• NCKDWSWLGOVRRK-UHFFFAOYSA-N 7-fluoro-3-(4-fluorophenyl)-4-hydroxy-2h-isoquinolin-1-one Chemical compound N1C(=O)C2=CC(F)=CC=C2C(O)=C1C1=CC=C(F)C=C1 NCKDWSWLGOVRRK-UHFFFAOYSA-N 0.000 description 1
• IQFUWYZHJUSZCQ-UHFFFAOYSA-N 7-fluoro-4-hydroxy-3-(4-methylsulfonylphenyl)-2h-isoquinolin-1-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(O)C2=CC=C(F)C=C2C(=O)N1 IQFUWYZHJUSZCQ-UHFFFAOYSA-N 0.000 description 1
• DEUDMUBGMGMJMA-UHFFFAOYSA-N 7-fluoro-4-hydroxy-3-(4-morpholin-4-ylphenyl)-2h-isoquinolin-1-one Chemical compound N1C(=O)C2=CC(F)=CC=C2C(O)=C1C(C=C1)=CC=C1N1CCOCC1 DEUDMUBGMGMJMA-UHFFFAOYSA-N 0.000 description 1
• GUFSUTDNJRQGHR-UHFFFAOYSA-N 7-fluoro-4-hydroxy-3-[3-(trifluoromethyl)phenyl]-2h-isoquinolin-1-one Chemical compound N1C(=O)C2=CC(F)=CC=C2C(O)=C1C1=CC=CC(C(F)(F)F)=C1 GUFSUTDNJRQGHR-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
• 206010003210 Arteriosclerosis Diseases 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 229910015900 BF3 Inorganic materials 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
• 101100505320 Caenorhabditis elegans gpa-16 gene Proteins 0.000 description 1
• 101100352919 Caenorhabditis elegans ppm-2 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• 208000031229 Cardiomyopathies Diseases 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
• VTVDNGVGQYFMGX-UHFFFAOYSA-N Cl.NCCOC1=C(NC(=O)C2=CC(F)=CC=C12)C1=CC=CC(=C1)C#N Chemical compound Cl.NCCOC1=C(NC(=O)C2=CC(F)=CC=C12)C1=CC=CC(=C1)C#N VTVDNGVGQYFMGX-UHFFFAOYSA-N 0.000 description 1
• UXGHUAWGQOUKLE-UHFFFAOYSA-N Cl.NCCOC1=C(NC(=O)C2=CC(F)=CC=C12)C1=CC=CC(Br)=C1 Chemical compound Cl.NCCOC1=C(NC(=O)C2=CC(F)=CC=C12)C1=CC=CC(Br)=C1 UXGHUAWGQOUKLE-UHFFFAOYSA-N 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
• PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
• LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
• 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
• 230000007035 DNA breakage Effects 0.000 description 1
• 239000012623 DNA damaging agent Substances 0.000 description 1
• 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
• 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
• 230000004568 DNA-binding Effects 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 201000008808 Fibrosarcoma Diseases 0.000 description 1
• 206010016935 Follicular thyroid cancer Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 208000010412 Glaucoma Diseases 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• 102000009465 Growth Factor Receptors Human genes 0.000 description 1
• 108010009202 Growth Factor Receptors Proteins 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 1
• 208000031226 Hyperlipidaemia Diseases 0.000 description 1
• 101100071331 Hypomyces subiculosus hpm8 gene Proteins 0.000 description 1
• WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 239000002841 Lewis acid Substances 0.000 description 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 102000001419 Melatonin receptor Human genes 0.000 description 1
• 108050009605 Melatonin receptor Proteins 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 239000004909 Moisturizer Substances 0.000 description 1
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• JRNVZBWKYDBUCA-UHFFFAOYSA-N N-Chlorosuccinimide Substances ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 1
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
• OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 208000005890 Neuroma Diseases 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• 208000035823 Non-specific autoimmune cerebellar ataxia without characteristic antibodies Diseases 0.000 description 1
• 108010089610 Nuclear Proteins Proteins 0.000 description 1
• 102000007999 Nuclear Proteins Human genes 0.000 description 1
• HDVPDKJPQGWYDH-UHFFFAOYSA-N OCCNC(O)=O.C(C)(C)(C)OC(C)(C)C Chemical compound OCCNC(O)=O.C(C)(C)(C)OC(C)(C)C HDVPDKJPQGWYDH-UHFFFAOYSA-N 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• 101700056750 PAK1 Proteins 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 239000004372 Polyvinyl alcohol Substances 0.000 description 1
• 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 229940124639 Selective inhibitor Drugs 0.000 description 1
• 201000010208 Seminoma Diseases 0.000 description 1
• 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 1
• 101710125350 Serine/threonine-protein kinase N1 Proteins 0.000 description 1
• 102100027910 Serine/threonine-protein kinase PAK 1 Human genes 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• 206010041067 Small cell lung cancer Diseases 0.000 description 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 206010042971 T-cell lymphoma Diseases 0.000 description 1
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 1
• 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
• 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
• 102000004243 Tubulin Human genes 0.000 description 1
• 108090000704 Tubulin Proteins 0.000 description 1
• 206010046851 Uveitis Diseases 0.000 description 1
• 101000988661 Xenopus laevis Hepatocyte nuclear factor 1-alpha-A Proteins 0.000 description 1
• 206010048218 Xeroderma Diseases 0.000 description 1
• LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 125000002015 acyclic group Chemical group 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 235000010419 agar Nutrition 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
• 125000004471 alkyl aminosulfonyl group Chemical group 0.000 description 1
• 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
• 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
• 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
• 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
• 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
• 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
• 125000004414 alkyl thio group Chemical group 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
• 239000000908 ammonium hydroxide Substances 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 238000011861 anti-inflammatory therapy Methods 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
• 208000011775 arteriosclerosis disease Diseases 0.000 description 1
• 125000003710 aryl alkyl group Chemical group 0.000 description 1
• 125000005100 aryl amino carbonyl group Chemical group 0.000 description 1
• 125000005141 aryl amino sulfonyl group Chemical group 0.000 description 1
• 125000004658 aryl carbonyl amino group Chemical group 0.000 description 1
• 125000005129 aryl carbonyl group Chemical group 0.000 description 1
• 125000005199 aryl carbonyloxy group Chemical group 0.000 description 1
• 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
• 125000004657 aryl sulfonyl amino group Chemical group 0.000 description 1
• 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
• 125000005110 aryl thio group Chemical group 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
• AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 238000012742 biochemical analysis Methods 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 125000006267 biphenyl group Chemical group 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• 239000012267 brine Substances 0.000 description 1
• XTEOJPUYZWEXFI-UHFFFAOYSA-N butyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC XTEOJPUYZWEXFI-UHFFFAOYSA-N 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 125000004432 carbon atom Chemical group C* 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
• KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 230000033077 cellular process Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 208000019065 cervical carcinoma Diseases 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 238000001311 chemical methods and process Methods 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 238000004296 chiral HPLC Methods 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
• 235000017803 cinnamon Nutrition 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
• 238000004140 cleaning Methods 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 229940125773 compound 10 Drugs 0.000 description 1
• 229940125758 compound 15 Drugs 0.000 description 1
• 229940125782 compound 2 Drugs 0.000 description 1
• 229940126086 compound 21 Drugs 0.000 description 1
• 229940126214 compound 3 Drugs 0.000 description 1
• 229940125898 compound 5 Drugs 0.000 description 1
• DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 229940111134 coxibs Drugs 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 125000004465 cycloalkenyloxy group Chemical group 0.000 description 1
• 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 1
• UVJHQYIOXKWHFD-UHFFFAOYSA-N cyclohexa-1,4-diene Chemical compound C1C=CCC=C1 UVJHQYIOXKWHFD-UHFFFAOYSA-N 0.000 description 1
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
• 239000000824 cytostatic agent Substances 0.000 description 1
• 230000001085 cytostatic effect Effects 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 238000007872 degassing Methods 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
• 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 1
• 125000004472 dialkylaminosulfonyl group Chemical group 0.000 description 1
• 125000004986 diarylamino group Chemical group 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 239000008298 dragée Substances 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 230000013020 embryo development Effects 0.000 description 1
• 210000003238 esophagus Anatomy 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 239000012894 fetal calf serum Substances 0.000 description 1
• 239000007941 film coated tablet Substances 0.000 description 1
• 239000007888 film coating Substances 0.000 description 1
• 238000009501 film coating Methods 0.000 description 1
• 238000002875 fluorescence polarization Methods 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
• 230000006870 function Effects 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 210000000232 gallbladder Anatomy 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 231100000024 genotoxic Toxicity 0.000 description 1
• 230000001738 genotoxic effect Effects 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• XDDAORKBJWWYJS-UHFFFAOYSA-N glyphosate Chemical compound OC(=O)CNCP(O)(O)=O XDDAORKBJWWYJS-UHFFFAOYSA-N 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
• 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
• 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
• 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
• 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
• 235000012907 honey Nutrition 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• 150000004679 hydroxides Chemical class 0.000 description 1
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
• VFOSDIOKPAJPOS-UHFFFAOYSA-N hydroxysulfanylmethanamine Chemical compound NCSO VFOSDIOKPAJPOS-UHFFFAOYSA-N 0.000 description 1
• 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
• 206010021198 ichthyosis Diseases 0.000 description 1
• MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 239000000677 immunologic agent Substances 0.000 description 1
• 229940124541 immunological agent Drugs 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000005040 ion trap Methods 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
• 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 150000002537 isoquinolines Chemical class 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 150000007517 lewis acids Chemical class 0.000 description 1
• 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
• YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
• 238000012417 linear regression Methods 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 231100000053 low toxicity Toxicity 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 235000001055 magnesium Nutrition 0.000 description 1
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000001819 mass spectrum Methods 0.000 description 1
• 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
• 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
• 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000001333 moisturizer Effects 0.000 description 1
• 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
• 230000003680 myocardial damage Effects 0.000 description 1
• 208000031225 myocardial ischemia Diseases 0.000 description 1
• SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 229920001206 natural gum Polymers 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 229960003966 nicotinamide Drugs 0.000 description 1
• 235000005152 nicotinamide Nutrition 0.000 description 1
• 239000011570 nicotinamide Substances 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 1
• 229960000572 olaparib Drugs 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 239000012044 organic layer Substances 0.000 description 1
• 239000012074 organic phase Substances 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 125000005968 oxazolinyl group Chemical group 0.000 description 1
• 125000004043 oxo group Chemical group O=* 0.000 description 1
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
• LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 239000001814 pectin Substances 0.000 description 1
• 235000010987 pectin Nutrition 0.000 description 1
• 229920001277 pectin Polymers 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 238000009521 phase II clinical trial Methods 0.000 description 1
• RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 1
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
• 239000002953 phosphate buffered saline Substances 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 229940068965 polysorbates Drugs 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
• 239000011736 potassium bicarbonate Substances 0.000 description 1
• 235000015497 potassium bicarbonate Nutrition 0.000 description 1
• 239000000276 potassium ferrocyanide Substances 0.000 description 1
• TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
• 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• CDXJNCAVPFGVNL-UHFFFAOYSA-N propyl 2,2,2-trifluoroacetate Chemical compound CCCOC(=O)C(F)(F)F CDXJNCAVPFGVNL-UHFFFAOYSA-N 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
• 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
• DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 206010038038 rectal cancer Diseases 0.000 description 1
• 208000020615 rectal carcinoma Diseases 0.000 description 1
• 230000010410 reperfusion Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 238000007086 side reaction Methods 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
• 229910001958 silver carbonate Inorganic materials 0.000 description 1
• 230000003007 single stranded DNA break Effects 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 239000012279 sodium borohydride Substances 0.000 description 1
• 229910000033 sodium borohydride Inorganic materials 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
• 229920003109 sodium starch glycolate Polymers 0.000 description 1
• 239000008109 sodium starch glycolate Substances 0.000 description 1
• 229940079832 sodium starch glycolate Drugs 0.000 description 1
• 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
• 238000010532 solid phase synthesis reaction Methods 0.000 description 1
• 239000012453 solvate Substances 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 229940032147 starch Drugs 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• 239000007940 sugar coated tablet Substances 0.000 description 1
• 238000009495 sugar coating Methods 0.000 description 1
• 229910052717 sulfur Chemical group 0.000 description 1
• 239000011593 sulfur Chemical group 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 238000001308 synthesis method Methods 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 239000003277 telomerase inhibitor Substances 0.000 description 1
• 208000001608 teratocarcinoma Diseases 0.000 description 1
• MTNPSDNKIAWMTB-UHFFFAOYSA-N tert-butyl N-[2-[3-(3-bromophenyl)-7-fluoro-1-phenylmethoxyisoquinolin-4-yl]oxyethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOc1c(nc(OCc2ccccc2)c2cc(F)ccc12)-c1cccc(Br)c1 MTNPSDNKIAWMTB-UHFFFAOYSA-N 0.000 description 1
• WFFKDRJBGFTXJT-UHFFFAOYSA-N tert-butyl N-[2-[3-(3-cyanophenyl)-7-fluoro-1-phenylmethoxyisoquinolin-4-yl]oxyethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOc1c(nc(OCc2ccccc2)c2cc(F)ccc12)-c1cccc(c1)C#N WFFKDRJBGFTXJT-UHFFFAOYSA-N 0.000 description 1
• AEFNGRAYPRIQDB-UHFFFAOYSA-N tert-butyl N-[2-[[3-(1,3-benzodioxol-5-yl)-7-fluoro-1-oxo-2H-isoquinolin-4-yl]oxy]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOc1c([nH]c(=O)c2cc(F)ccc12)-c1ccc2OCOc2c1 AEFNGRAYPRIQDB-UHFFFAOYSA-N 0.000 description 1
• RIWVKGYCUIGRAB-UHFFFAOYSA-N tert-butyl N-[2-[[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-fluoro-1-oxo-2H-isoquinolin-4-yl]oxy]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOc1c([nH]c(=O)c2cc(F)ccc12)-c1ccc2OCCOc2c1 RIWVKGYCUIGRAB-UHFFFAOYSA-N 0.000 description 1
• HMNHVXIBGBFCIC-UHFFFAOYSA-N tert-butyl N-[2-[[3-(3,4-difluorophenyl)-7-fluoro-1-oxo-2H-isoquinolin-4-yl]oxy]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOc1c([nH]c(=O)c2cc(F)ccc12)-c1ccc(F)c(F)c1 HMNHVXIBGBFCIC-UHFFFAOYSA-N 0.000 description 1
• CIAVIQWERILCMU-UHFFFAOYSA-N tert-butyl N-[2-[[3-(3-bromo-4-morpholin-4-ylphenyl)-7-fluoro-1-oxo-2H-isoquinolin-4-yl]oxy]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOc1c([nH]c(=O)c2cc(F)ccc12)-c1ccc(N2CCOCC2)c(Br)c1 CIAVIQWERILCMU-UHFFFAOYSA-N 0.000 description 1
• HBBQVUWLYICPEY-UHFFFAOYSA-N tert-butyl N-[2-[[3-(4-bromophenyl)-7,8-difluoro-1-oxo-2H-isoquinolin-4-yl]oxy]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOc1c([nH]c(=O)c2c(F)c(F)ccc12)-c1ccc(Br)cc1 HBBQVUWLYICPEY-UHFFFAOYSA-N 0.000 description 1
• ZSCBABMAWZFWHM-UHFFFAOYSA-N tert-butyl N-[2-[[3-(4-chlorophenyl)-7-fluoro-1-oxo-2H-isoquinolin-4-yl]oxy]ethyl]carbamate Chemical compound C(C)(C)(C)OC(NCCOC1=C(NC(C2=CC(=CC=C12)F)=O)C1=CC=C(C=C1)Cl)=O ZSCBABMAWZFWHM-UHFFFAOYSA-N 0.000 description 1
• NWGOOHZJYZYTOW-UHFFFAOYSA-N tert-butyl N-[2-[[7-fluoro-1-oxo-3-(4-pyrrolidin-1-ylphenyl)-2H-isoquinolin-4-yl]oxy]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOc1c([nH]c(=O)c2cc(F)ccc12)-c1ccc(cc1)N1CCCC1 NWGOOHZJYZYTOW-UHFFFAOYSA-N 0.000 description 1
• LBJDVUTVRADCSQ-UHFFFAOYSA-N tert-butyl N-[2-[[7-fluoro-1-oxo-3-[3-(trifluoromethyl)phenyl]-2H-isoquinolin-4-yl]oxy]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOc1c([nH]c(=O)c2cc(F)ccc12)-c1cccc(c1)C(F)(F)F LBJDVUTVRADCSQ-UHFFFAOYSA-N 0.000 description 1
• WYZJBBUHSTVEOX-UHFFFAOYSA-N tert-butyl N-[2-[[7-fluoro-3-(3-fluoro-4-methoxyphenyl)-1-oxo-2H-isoquinolin-4-yl]oxy]ethyl]carbamate Chemical compound COc1ccc(cc1F)-c1[nH]c(=O)c2cc(F)ccc2c1OCCNC(=O)OC(C)(C)C WYZJBBUHSTVEOX-UHFFFAOYSA-N 0.000 description 1
• ZMZRSMWESPEHJD-UHFFFAOYSA-N tert-butyl N-[2-[[7-fluoro-3-(4-fluorophenyl)-1-oxo-2H-isoquinolin-4-yl]oxy]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOc1c([nH]c(=O)c2cc(F)ccc12)-c1ccc(F)cc1 ZMZRSMWESPEHJD-UHFFFAOYSA-N 0.000 description 1
• PMAUMWKKQSXPHO-UHFFFAOYSA-N tert-butyl N-[2-[[7-fluoro-3-(4-methylsulfonylphenyl)-1-oxo-2H-isoquinolin-4-yl]oxy]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOc1c([nH]c(=O)c2cc(F)ccc12)-c1ccc(cc1)S(C)(=O)=O PMAUMWKKQSXPHO-UHFFFAOYSA-N 0.000 description 1
• RSEJJQVZDOKLKZ-UHFFFAOYSA-N tert-butyl N-[2-[[7-fluoro-3-(4-morpholin-4-ylphenyl)-1-oxo-2H-isoquinolin-4-yl]oxy]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOc1c([nH]c(=O)c2cc(F)ccc12)-c1ccc(cc1)N1CCOCC1 RSEJJQVZDOKLKZ-UHFFFAOYSA-N 0.000 description 1
• LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
• WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
• XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 1
• CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
• HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
• 210000001519 tissue Anatomy 0.000 description 1
• XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 230000000472 traumatic effect Effects 0.000 description 1
• 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
• 230000005747 tumor angiogenesis Effects 0.000 description 1
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
• 238000000825 ultraviolet detection Methods 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 description 1
• 229950011257 veliparib Drugs 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 238000003260 vortexing Methods 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 229940102001 zinc bromide Drugs 0.000 description 1
• 235000005074 zinc chloride Nutrition 0.000 description 1
• 239000011592 zinc chloride Substances 0.000 description 1
• GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1